first glp-1 approved for weight loss BREAKING: The FDA has the oral pill obesity, marking a major milestone in the weight-loss drug market and a potential inflection point for treatment access. The daily pill The promise and peril of

Rare serious risks include pancreatitis and gallbladder issues

Particularly for tirzepatide, in the mixed effects model on a subset of the data with therapy duration greater than 180 days, there is a positive coefficient with therapy duration and weight regain after cessation with a significant P value

1 for GLP-1s Novo needed this boost

You might just need a little protein

While many protein drinks on the market use a milk protein called casein, OIKOS FUSION uses whey protein specifically because it digests rapidly and has a naturally higher leucine content

Pfizer was hoping to throw its hat into the ring, but now it seems the pharma company has taken itself out of the running at least for now